Clinical Report: Exploring the Role of Antimetabolites in Mitigating Allosensitization

Overview

This study investigates the impact of maintenance immunosuppression on allosensitization in kidney retransplant recipients. The findings indicate a difference in calculated panel reactive antibodies (cPRA) at retransplantation based on the type of immunosuppression used.

Background

Kidney retransplantation is increasingly common due to the limited lifespan of grafts. Allosensitization complicates retransplantation by prolonging waiting times and negatively impacting outcomes. Understanding the optimal immunosuppressive strategies post-graft failure is crucial for improving patient management.

Data Highlights

Key Findings

• 16% of kidney transplantations in the cohort were retransplantations.
• The burden of immunosuppression decreased significantly from graft failure to retransplantation.
• Allosensitization increased, with a notable rise in the number of HLA-antibodies.
• Intake of antimetabolites was associated with a lower cPRA at retransplantation.
• Waiting time to retransplantation showed only a weak correlation with allosensitization.

Clinical Implications

The findings present data on the association of antimetabolites with cPRA in kidney retransplant recipients.

Conclusion

The study presents data on the association of antimetabolites with allosensitization in kidney retransplantation.

Related Resources & Content

1. Frontiers in Immunology, 2026 -- Highly sensitized kidney transplant candidates: integrating acceptable mismatch, desensitization, imlifidase, and emerging immune-cell targeting strategies
2. Frontiers in Immunology, 2026 -- Risk-adapted HLA delisting and imlifidase-enabled deceased-donor kidney transplantation in highly sensitized kidney transplant candidates: a German expert consensus report
3. Frontiers in Immunology, 2026 -- Metabolic Dysregulation and Antibody-Mediated Rejection After Kidney Transplantation: Interacting Mechanisms and Emerging Clinical Strategies
4. ScienceDirect, 2025 -- The impact of immunosuppression withdrawal strategies on sensitization and safety outcomes after kidney transplant failure: A systematic review with meta-analysis
5. KDIGO, 2023 -- Challenges in the management of the kidney allograft: from decline to failure: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
6. Frontiers in Immunology — Outcomes of Belatacept Based Quadruple Immunosuppression Therapy in Kidney Transplant Recipients with Persistent Alloimmune Response: A Single Center Observational Study
7. Managing the failing renal allograft: navigating a complex topography
8. Challenges in the management of the kidney allograft: from decline to failure: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
9. The impact of immunosuppression withdrawal strategies on sensitization and safety outcomes after kidney transplant failure: A systematic review with meta-analysis - ScienceDirect